ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
5
views
0
references
Top references
cited by
3
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
2,850
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer
Author(s):
GR Oxnard
,
SS Ramalingam
,
MJ Ahn
,
M-J Ahn
Publication date:
2015
Journal:
J Clin Oncol
Read this article at
ScienceOpen
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
25th European Students' Conference
Data availability:
ScienceOpen disciplines:
Medicine
Comments
Comment on this article
Sign in to comment
Similar content
2,850
Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours (CAURAL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)
Authors:
Abstract 761: changing the paradigm for treating drug resistance in NSCLC: novel combinations of AZD6094, a selective MET inhibitor, and an irreversible, selective (EGFRm/T790M) EGFRTKI, AZD9291
Authors:
C. M. D'Cruz
,
E Barry
,
R. HENRY
A phase IB study of the combination of selumetinib (AZD6244, ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC)
Authors:
A Krishnamurthy
,
Anuradha Krishnamurthy
,
A Dasari
…
See all similar
Cited by
3
Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib
Authors:
Valentina Mazza
,
Federico Cappuzzo
Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors
Authors:
Vera Hirsh
Major milestones in translational oncology
Authors:
Tommaso Dragani
,
Antoni Castells
,
Vathany Kulasingam
…
See all cited by